RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Jorge S. Reis‐Filho et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancerElena Élez, Rodrigo A. Toledo, Javier Ros et al.|Nature Medicine|2022Cited by 111
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High AltitudesCarlota Arenillas, Nicole Bechmann, Lucía Celada et al.|Cancer Discovery|2025Cited by 7
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Charles W. Abbott et al.|Clinical Cancer Research|2025Cited by 1